Reader Rants 'n' Raves

XIENCE™ V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE™ V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS® paclitaxel-eluting coronary stent system. In this trial of more than 1,000 patients, XIENCE V demonstrated a 45 percent reduction in the risk of major adverse cardiac events (MACE) and a 32 percent reduction in the risk of target vessel failure (cardiac events related to the treated vessel) at two years as compared to TAXUS. The SPIRIT III two-year results were presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the late-breaking clinical trials session at EuroPCR 2008.12:08 PM on May 15